| Name | Title | Contact Details |
|---|
AprotekUSA turns YOUR liquid waste stream into a solid in real-time. SAVE MONEY💲 BY SOLIDIFYING YOUR SLUDGE 🌎We specialize in the recycling and manufacture of super-absorbent products. Since 2013, weve been working with public and private companies to solve their problems relating to sludge containment, water absorption and retention, impermeability and liquid solidification. Our core business? MUDS and LIQUID DEBLAYS. 💩 Our range of APROMUD® super-settlers is formidable when it comes to solidifying sludge, whatever its origin or composition. Sludge from construction sites, WWTPs, HDD, tunneling, mines & quarries, pond cleaning, concrete plants, drilling we have developed low-carbon solutions to make it easier for you to handle, transport and recycle your sludge while saving you . 🌱
HPI redefines what is possible with self-funded health plans. As a third-party administrator, we partner with health plan brokers and employers to provide innovative self-funding strategies and customized plans tailored to each clients needs and population. Our solutions give employers greater cost transparency and control, while elevating the member experience.
A family-owned, integrated agri-business with cattle, citrus, farming, forestry, hunting and land and water resource management.
Aim Sky High Academy is a Forbes featured, award-winning dance organisation featured in Forbes and Business Insider that aims to socially mobilise children and young people by teaching lifelong transferable skills through dance. Our students are current UK Hip Hop Dance Champions and have been used by Justin Bieber, Stormzy, Giggs and more. Awards won include: - Lloyds Bank School for Social Entrepreneurs Scale-Up Award 2016 - Social Enterprise UK Inspiring Youth Award 2015 - UDO World Champions 2014 - UDO European Champions 2014/15/16/19 - Barclays School for Start Ups Social Enterprise Winner 2013 ...and more. Come and follow our journey!
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.